Is it really a matter of simple dualism? Corticotropin-releasing factor receptors in body and mental health by Janssen, D. & Kozicz, L.T.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/118700
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
REVIEW ARTICLE
published: 12 March 2013
doi: 10.3389/fendo.2013.00028
Is it really a matter of simple dualism?
Corticotropin-releasing factor receptors in body and
mental health
Donny Janssen1 andTamás Kozicz 1,2,3*
1 Department of Cellular Animal Physiology, Donders Institute for Brain, Cognition and Behavior, Nijmegen, Netherlands
2 Department of Anatomy, Donders Institute for Brain, Cognition and Behavior, Nijmegen, Netherlands
3 Human Genetics Center, Tulane University, New Orleans, LA, USA
Edited by:
Hubert Vaudry, University of Rouen,
France
Reviewed by:
James A. Carr, TexasTech University,
USA
Rafael Vazquez-Martinez, University
of Cordoba, Spain
*Correspondence:
Tamás Kozicz, Department of
Anatomy, Radboud University
Nijmegen Medical Centre, P.O. Box
9101, 6500 HB Nijmegen,
Netherlands.
e-mail: t.kozicz@anat.umcn.nl
Physiological responses to stress coordinated by the hypothalamo-pituitary-adrenal axis
are concerned with maintaining homeostasis in the presence of real or perceived chal-
lenges. Regulators of this axis are corticotrophin releasing factor (CRF) and CRF related
neuropeptides, including urocortins 1, 2, and 3. They mediate their actions by binding to
CRF receptors (CRFR) 1 and 2, which are located in several stress-related brain regions.
The prevailing theory has been that the initiation of and the recovery from an elicited stress
response is coordinated by two elements, viz. the (mainly) opposing, but well balanced
actions of CRFR1 and CRFR2. Such a dualistic view suggests that CRF/CRFR1 controls
the initiation of, and urocortins/CRFR2 mediate the recovery from stress to maintain body
and mental health. Consequently, failed adaptation to stress can lead to neuropathology,
including anxiety and depression. Recent literature, however, challenges such dualistic and
complementary actions of CRFR1 and CRFR2, and suggests that stress recruits CRF sys-
tem components in a brain area and neuron specific manner to promote adaptation as
conditions dictate.
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“The idea would be not to abolish the CRFR1 receptor’s response to
the brain’s stress hormone but to bring it into the normal range so that
it would have appropriate levels of anxiety and stress as conditions
dictate.”
Wylie W. Vale (1941–2012)
INTRODUCTION
The concept of stress and adaptation was first observed in 1936
and further defined in 1951 (Selye, 1936, 1951). After exposure
to a stressor, corticotrophin releasing factor (CRF) is released by
endocrine cells of the paraventricular nucleus (PVN) of the hypo-
thalamus into the portal vessels thereby stimulating the release of
adrenocorticotropic hormone (ACTH) by the anterior pituitary.
Subsequently, circulating ACTH stimulates secretion of glucocor-
ticoids from the adrenal gland (Vale et al., 1981). In the 1980s,
the group of Vale isolated the 41-residue CRF peptide from the
ovine hypothalamus (Vale et al.,1981) and throughout the decades,
many members of the CRF family have been identified, including
urocortin 1 (Ucn1), urocortin 2 (Ucn2), and urocortin 3 (Ucn3).
The urocortins differ in their tissue distribution and receptor phar-
macology (Vaughan et al., 1995; Hsu and Hsueh, 2001; Lewis et al.,
2001; Reyes et al., 2001). First shown to be important regulators of
the endocrine stress response, the CRF family of neuropeptides is
now known to play a role in diverse roles of homeostatic balance,
important in mobilization of resources and behaviors during stress
(Bale and Vale, 2004). In addition, members of the CRF peptide
family play a role in regulation of food intake and satiety, as well
as gastrointestinal tract motility, vascular tone, and development,
and also acoustic and cardiac function (Heinrichs et al., 1992;
Spina et al., 1996; Parkes et al., 1997; Okosi et al., 1998; Koob and
Heinrichs, 1999; Maillot et al., 2000; Terui et al., 2001; Vetter et al.,
2002; Inoue et al., 2003).
The actions of these peptides are initiated by binding and acti-
vating G-protein coupled receptors, CRFR1 and CRFR2, which
display distinct affinity for members of the CRF peptide family,
with CRF and Ucn1 binding to both receptors, while Ucn2 and
3 selectively bind to CRFR2 (Vaughan et al., 1995; Lewis et al.,
2001). Besides CRF receptors (CRFRs) and their cognate ligands,
another peptide that plays an important role in the neurobiol-
ogy of the CRF family of neuropeptides is CRF binding protein
(CRF-BP), a 37 kDa N-linked glycoprotein which binds both CRF
and Ucn1 with high affinity (Orth and Mount, 1987; Boorse et al.,
2005).
In this review, we highlight evidence supporting the notion of
a dualistic action of CRFR1 and CRFR2 in mediating an adequate
physiological, endocrine, and behavioral response to stress, fol-
lowed by recent studies challenging this view. As this function is
largely dependent upon structure, we will start with a short sum-
mary on the functional neuroanatomy of CRF system components
followed by data on the animals’ stress (mal)adaptation response.
DISTRIBUTION OF CRF SYSTEM COMPONENTS
CRF
The distribution of CRF is consistent with its hypothe-
sized functions of controlling the endocrine, physiological, and
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behavioral response to stress, and it is abundantly expressed in the
mammalian brain, with especially high amounts of the peptide
concentrated in the parvocellular division of the hypothalamic
PVN, bed nucleus of the stria terminalis, central amygdala, lateral
hypothalamus, and locus coeruleus (Merchenthaler et al., 1982;
Morin et al., 1999). Dense CRF fibers have been located in the lat-
eral septum, bed nucleus of the stria terminalis, central nucleus of
the amygdala, median eminence, the raphe nuclei, and the spinal
cord (Merchenthaler et al., 1982; Morin et al., 1999; Korosi et al.,
2007).
UROCORTIN 1
Urocortin 1 is related to CRF, with a sequence identify of 45%
(Vaughan et al.,1995). It binds CRFR2 with 100-fold higher affinity
than CRF does, indicating that this peptide might be an endoge-
nous ligand for CRFR2 (Vaughan et al., 1995; Chalmers et al.,
1996; Perrin and Vale, 1999). The most dominant sites of Ucn1
expression in the mammalian brain includes the centrally pro-
jecting Edinger–Westphal nucleus (EWcp) in the rostroventral
midbrain, the supraoptic nucleus in the hypothalamus and the
superior lateral olive, which have been confirmed in mammalian
and non-mammalian species (Iino et al., 1997; Takahashi et al.,
1998; Bittencourt et al., 1999; Kozicz et al., 2002, 2008, 2011a;
Ryabinin et al., 2005). Networks of Ucn1 fibers have been identi-
fied in the lateral septum, internal layer of the median eminence,
dorsal raphe nucleus, and the spinal cord, with scattered fibers
located in the hypothalamus, hippocampus, cortex, and posterior
pituitary (Kozicz et al., 1998; Bittencourt et al., 1999; Iino et al.,
1999; Morin et al., 1999; Korosi et al., 2007).
UROCORTIN 2
Urocortin 2 is a 38 amino acid peptide, which selectively binds
CRFR2 (Reyes et al., 2001). Ucn2 mRNA shows a distinct sub-
cortical distribution, including regions known to be involved in
physiological and behavioral responses to stress, such as the PVN,
locus coeruleus, and the arcuate nucleus (Reyes et al., 2001). Ucn2
mRNA partially overlaps with the expression of CRF in the PVN
and Ucn1 in the brainstem and spinal motor nuclei (Swanson
et al., 1983; Bittencourt et al., 1999; Reyes et al., 2001). To date no
reliable Ucn2 immunohistochemistry has been performed (due
to lack of reliable and specific antibody against Ucn2), hence the
distribution of Ucn2 immunoreactive fiber terminals remains to
be mapped.
UROCORTIN 3
Urocortin 3 is just like Ucn2 a 38 amino acid peptide which
selectively binds CRFR2 (Lewis et al., 2001). Ucn3 expressing neu-
rons have a limited distribution compared to CRF and Ucn1, and
the peptide is mostly located in forebrain regions, including the
preoptic region, hypothalamus, and amygdala. Two areas of the
hypothalamus express Ucn3, the first population being neurons in
the preoptic nucleus and the second group of neurons are associ-
ated with the fornix (“perifornical”Ucn3 neuron population) near
the PVN of the hypothalamus (Lewis et al., 2001; Li et al., 2002).
More Ucn3 expressing neurons are located in the medial amygdala
and paraolivary nucleus (Lewis et al., 2001; Li et al., 2002). Dens-
est innervation of Ucn3 includes the ventromedial hypothalamus,
lateral septum, posterior division of the bed nucleus of the stria
terminalis and the medial amygdala, which are areas known to
express CRFR2 (Lewis et al., 2001; Li et al., 2002).
CRF BINDING PROTEIN
CRF binding protein is relatively widely expressed in the mam-
malian brain, including the cerebral cortex, subcortical limbic
system, various sensory relays, raphe nuclei, hypothalamus, and
pituitary (Orth and Mount, 1987; Behan et al., 1989; Potter et al.,
1992). In humans, the CRF-BP has been found in the liver and
in the circulation, where it inactivates CRF and/or Ucn1. The
exact function of the protein is still unknown, but it has been
proposed that CRF-BP prevents inappropriate pituitary-adrenal
activation, e.g., during pregnancy (Potter et al., 1991). Upon bind-
ing to CRF-BP, CRF forms a dimer complex and is thought to
modulate the endocrine activity of CRF (Lowry et al., 1996). In
rat pituitary cells, recombinant CRF-BP blocks secretion of ACTH
(Potter et al., 1991). The binding proteins have also been detected
in brain regions not associated with CRF actions, suggesting it may
have other functions independent from CRF (Potter et al., 1992;
Cortright et al., 1995; Bale and Vale, 2004).
CRFR1
CRFR1 is a 415 amino acid peptide in mammals and has a wide-
spread expression in stress-related areas located in the central
nervous system (CNS). CRFR1 mRNA has been located in the
cortex, cerebellum, hippocampus, amygdala, olfactory bulb, lat-
eral septum, thalamus, basal ganglia, the raphe nuclei, pituitary,
brain stem, and spinal cord (Van Pett et al., 2000; Korosi et al.,
2006, 2007; Justice et al., 2008; Kuhne et al., 2012). Outside the
CNS, the CRFR1 is expressed in the thymus, spleen, skin, ovary,
testis, gastrointestinal tissue, and adrenal gland (Dufau et al., 1993;
Nappi and Rivest, 1995; Slominski et al., 1995; Baigent and Lowry,
2000; Muller et al., 2001; Chatzaki et al., 2004).
A recent study, which aimed at accurately determining the pres-
ence of CRFR1 in the brain, revealed that this receptor is present in
glutamatergic neurons of the cortex and hippocampus, in gamma-
aminobutyric acid containing neurons of the reticular thalamic
nucleus, globus pallidus, and septum, and in dopaminergic neu-
rons of the substantia nigra pars compacta and ventral tegmental
area. It is also expressed in few serotonergic neurons of the dorsal
and media raphe nuclei (Refojo et al., 2011).
CRF RECEPTOR 2
CRF receptor 2 is a 397–437 amino acid protein in mammals and
it is abundantly expressed in both the CNS and in the periphery
(Kishimoto et al., 1995; Lovenberg et al., 1995b; Kostich et al.,
1998; Palchaudhuri et al., 1999; Van Pett et al., 2000; Korosi et al.,
2007; Justice et al., 2008; Kuhne et al., 2012). In the CNS, CRFR2 is
expressed in the olfactory bulb, hippocampus, amygdala, septum,
the dorsal and median raphe nuclei, cortex, pituitary, and spinal
cord (Palchaudhuri et al., 1999; Bittencourt and Sawchenko, 2000;
Van Pett et al., 2000; Korosi et al., 2006, 2007; Lukkes et al., 2011).
In the periphery, the receptor has been identified in the retina,
heart, skeletal muscle, vasculature, adrenal gland, and gastroin-
testinal tissue (Lovenberg et al., 1995a; Palchaudhuri et al., 1999;
Muller et al., 2001; Chatzaki et al., 2004).
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Despite the fact that the distribution of CRFR1 and CRFR2
overlaps in the brain, clear distinctions can be made among brain
subregions. For example, the CRFR1 receptor is expressed in
the basolateral nucleus of the amygdala, while both CRFR1 and
CRFR2 are present in the medial nucleus of the amygdala (Bitten-
court and Sawchenko, 2000; Van Pett et al., 2000). Interestingly,
mRNA of CRFR2 has been discovered in non-neuronal structures
as well, like the choroid plexus and cerebral arterioles (Lovenberg
et al., 1995a). In the cerebral arteries and arterioles, stimulation
of CRFR2 leads to an increased cerebral blood flow (De Michele
et al., 2005).
EVIDENCE SUPPORTING A DUALISTIC ACTION OF CRFR1
AND CRFR2 DURING STRESS (MAL)ADAPTATION
STRESS
Stress has been defined as various physiologic alterations, includ-
ing misbalance of homeostasis and activation of the hypothalamo-
pituitary-adrenal (HPA)-axis (Selye, 1936, 1951; Dallman et al.,
1987). Upon exposure to a stressor, the HPA-axis is activated by
the release of CRF into portal vessels and subsequently acts upon
the CRFR1 located in the anterior pituitary (Turnbull and Rivier,
1997; Vale et al., 1997). The initial understanding on the biological
significance of CRF system components governing the endocrine
stress response has come from various genetically modified animal
models. As follows we will overview these animal models.
CRF knockout
In order to assess the central physiological role of CRF a knockout
model was created (Muglia et al., 1995). Mice lacking CRF show
decreased glucocorticoid levels after exposure to stress, showing
the importance of CRF in regulating the HPA-axis (Muglia et al.,
1995; Venihaki and Majzoub, 1999). However, interpretation of
data from this animal model is significantly hampered/influenced
by compensatory changes in other members of the CRF system.
For example, in the absence of CRF, Ucn1 levels in the EWcp are
elevated, while distribution remains unchanged (Weninger et al.,
1999, 2000).
CRF overexpression
In order to study chronic activation of the HPA-axis, two indepen-
dent CRF overexpressing mouse lines were created (Stenzel-Poore
et al., 1992; Groenink et al., 2002). Both lines revealed elevated
basal plasma corticosterone levels in response to stress. Delayed
and attenuated HPA-axis hormone responses to stress, which
might be the result of HPA-axis desensitization, were reported
in the mice created by Stenzel-Poore et al. (Coste et al., 2001).
Ucn1 knockout
Two independent Ucn1 knockout models were generated by two
groups (Vetter et al., 2002; Wang et al., 2002). Both lines have nor-
mal endocrine stress responses, supporting the notion that Ucn1
has a minor or no role in stress induced activation of the HPA-
axis. It has been proposed that Ucn1 plays a role in adaptation to
stress, rather than initiating the stress response. The fact that Ucn1
KO mice have impaired adaptation to repeated stress supports this
notion (Zalutskaya et al., 2007).
Ucn2 knockout
Ucn2 knockout model showed that HPA-axis activity was nor-
mal in male and female mice deficient for Ucn2 (Breu et al.,
2012). Stress induced release of corticosterone was equal between
knockout and wild type animals. Interestingly, a gender specific
phenotype was detected in Ucn2 deficient mice. Females, but not
males, lacking Ucn2 show a significant increase in basal daily
rhythms of ACTH and corticosterone (Chen et al., 2006). It is
known that CRFR2 can modulate the HPA-axis, however, Ucn2
deficiency does not seem to have an impact on the stress induced
activation of the axis (Breu et al., 2012).
Ucn3 knockout
Ucn3 knockout mouse model recently showed that absence of
Ucn3 does not have an impact on basal activity of the HPA-axis, as
corticosterone levels remained unchanged when compared to wild
type littermates (Deussing et al., 2010). After exposure to stress, the
corticosterone levels in Ucn3 knockout and wild type mice were
equal, which resulted in an operational negative feedback loop of
corticosterone on the HPA-axis (Deussing et al., 2010).
Multiple Ucn knockouts
The importance of the urocortins in the stress system was con-
firmed by multiple urocortin knockout studies. A double knockout
of Ucn1 and 2 in mice showed equal basal corticosterone, but ele-
vated levels after exposure to stress (Neufeld-Cohen et al., 2010a).
However, the elevated corticosterone levels after exposure to stress
were not observed in an urocortin 1, 2, and 3 triple knock-
out (Neufeld-Cohen et al., 2010b). These mice deficient for the
urocortins were unable to recover properly and this was paired
with dysregulated serotonergic function in stress-related neuronal
circuits (Neufeld-Cohen et al., 2010b).
CRFR1 knockout
Two independent lines of CRFR1 knockout lines have demon-
strated the importance of CRFR1 in regulation of the HPA-axis
in response to stress. KO mice in both lines show an attenuated
response to restraint stress by a minimal increase in ACTH and
corticosterone. However, basal levels in the CRFR1 null mice are
equal between KO and wild type littermates (Smith et al., 1998;
Timpl et al., 1998).
CRFR2 knockout
CRFR2 knockout mice reveal a role for CRFR2 in regulating HPA-
axis activation in response to stress, but it appears initiation of
the response seems to be normal. These null mice show an early
termination of ACTH release, suggesting a role for CRFR2 in
maintaining activation of the HPA-axis (Coste et al., 2000). Fur-
thermore, coping with stressors seems to be reduced in CRFR2
KO mice (Coste et al., 2000). Mice deficient for CRFR2 are
also hypersensitive to stress, which leads to increased anxiety-like
behaviors (Bale et al., 2000; Gammie et al., 2005). Mutant CRFR2
mice have increased CRF mRNA in the central amygdala and
increased Ucn-1 and -3 in the EWcp and lateral perifornical region,
respectively suggesting a compensatory activation of extrahypo-
thalamic CRF and Ucn systems (Bale et al., 2000, 2002a; Kozicz,
2009). Chronic activation of CRFR2 also promotes an anxiety-like
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state, with attenuated behavioral and HPA-axis responses to stress
(Neufeld-Cohen et al., 2012).
CRFR1 and 2 double knockout
CRFR1 and CRFR2 double knockout mice show the central role
of these receptors in the stress response system. In the absence of
both receptors, the double knockout mice show an impaired HPA-
axis activation in response to stress (Preil et al., 2001; Bale et al.,
2002b). Further, ACTH and corticosterone levels after exposure
to stress are lowered in the double knockout mice compared to
CRFR1 deficient mice, suggesting a role for CRFR2 in mediating
HPA-axis sensitivity (Coste et al., 2000; Bale et al., 2002b).
ANXIETY
The CRF system has been proposed to be involved in the devel-
opment of anxiety-related disorders. Cumulative evidence relates
dysregulation of CRF systems to the etiology and pathobiology of
stress-associated diseases, including anxiety. The following stud-
ies which are related to anxiety- and depressive-like behaviors are
summarized in Table 1.
CRF knockout
Surprisingly, no behavioral abnormalities have been reported with
the CRF knockouts generated by Muglia et al. (1995). Similarly,
anxiety-like behavior is the same between knockout and wild type
animals under normal and stressful conditions in another CRF
deficient mouse created by Weninger et al. (1999). Interestingly,
CRFR antagonists have an anxiolytic effect in CRF knockout ani-
mals, suggesting that CRFR1 activation is crucial to induce anxiety,
while CRF itself may not. These data point toward the significance
of another CRFR ligand, like Ucn1, or a yet unidentified neuropep-
tide, compensating for CRF deficiency in the brain (Weninger et al.,
1999; Kozicz, 2007; Kozicz et al., 2011b).
CRF overexpression
In the model created by Stenzel-Poore et al. (1992), increased
anxiety-like and decreased exploratory behavior was observed
(Heinrichs et al., 1997; van Gaalen et al., 2002). This increase
in anxiety-like behavior could be reversed by administration of
CRF antagonist alpha-helical CRF (Stenzel-Poore et al., 1994).
Removing the adrenal gland in these animals did not inhibit the
anxiogenic effects of CRF overexpression, although corticosterone
levels were normalized. This suggests that behavioral effects caused
by CRF overexpression are mediated by CRF and CRFRs, rather
than being affected by corticosterone (Heinrichs et al., 1997).
Along these lines, Refojo et al. (2011) demonstrated that overex-
pression of limbic CRF in CRF-COECamk2aCre mice (Camk2aCre,
Cre driven by the calcium/calmodulin-dependent protein kinase
type II alpha chain promoter) resulted in increased anxiety-like
behavior too, suggesting that limbic CRF in particular would be
instrumental in mediating anxiety-like behavior. To date, no data
is available on anxiety-like behavior of the CRF overexpressing
mice created by Groenink et al. (2002).
Ucn1 knockout
The behavioral phenotype of Ucn1 KO mice is controversial.
The group of Wang et al. (2002) have shown no differences in
anxiety-like behavior, whereas Vetter et al. (2002) have demon-
strated that Ucn1 deficient animals display increased anxiety-like
behavior.
Ucn2 knockout
Ucn2 knockout mice have revealed no significant changes in
anxiety-like behavior. However, when investigating social activ-
ities, it was seen that male Ucn2 deficient mice had more pas-
sive social interactions and reduced aggressiveness compared to
wild type littermates, suggesting that Ucn2 may rather modulate
aggressive behavior in male mice (Breu et al., 2012).
Ucn3 knockout
Ucn3 knockout mice created by Deussing et al. (2010) showed
unchanged anxiety-related behaviors compared to wild type mice.
However, based on the prevalent expression of Ucn3 through-
out the accessory olfactory bulb and altered social discrimination
abilities of male and female Ucn3 knockout mice, it has been
suggested that Ucn3 plays a role in processing of social cues and
establishment of social memories (Deussing et al., 2010).
Multiple Ucn knockout
Urocortin 1 and 2 double knockout mouse model has demon-
strated an anxiolytic phenotype (Neufeld-Cohen et al., 2010a). A
further reduction in anxiety-like behavior was observed after dou-
ble Ucn1/Ucn2 deficient mice were exposed to acute stress, and
this reduction in anxiety was correlated with levels of serotonin
in anxiety-related brain regions (Neufeld-Cohen et al., 2010a).
Remarkably, the triple urocortin knockout mouse showed an
increase in anxiety-like behavior 24 h post-stress. This increase
in anxiety in triple urocortin knockout mice was also associ-
ated with serotonergic function in stress-linked neurocircuits. It
has been suggested that Ucn3 is pivotal to the observed phe-
notype of the triple knockout model (Neufeld-Cohen et al.,
2010b).
CRFR1 knockout
Three studies reported that mice deficient for CRFR1 exhibited,
what seemed to be, reduced anxiety-like behavior. In different
tests of spontaneous anxiety, open field (a measure of exploratory
behavior and general activity), light-dark box (based on the aver-
sion of mice to well illuminated areas and on exploratory behavior
in response to stressors), defensive withdrawal (a measure of con-
flict between exploratory behavior and retreat), and elevated plus
maze (based on the aversion for open and elevated areas and
on exploratory behavior in novel areas), which normally inhibit
behavioral activity, CRFR1 deficient mice showed heightened lev-
els of locomotion consistent with anxiety-like behavior (Smith
et al., 1998; Timpl et al., 1998; Contarino et al., 1999). The anx-
iolytic effect of CRFR1 deficient mice seems to be mediated by
reduced CRFR1 expression in the basolateral amygdala (Sztain-
berg et al., 2010). Furthermore, stress induced hormone secretion
showed that CRFR1 knockout mice had reduced levels of ACTH
and corticosterone, providing evidence that CRFR1 mediates anx-
iety and stress induced-hormone activation (Smith et al., 1998;
Timpl et al., 1998). Opposite effects were found in CRFR1Camk2aCre
mice generated by Muller et al. (2003) in which Cre mediated dele-
tion of CRFR1 starts in the second week of postnatal life. After
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Table 1 | Summary of animal models targeting CRF system components.
Experimental procedure Specificity Anxiety Depression Reference
CRF KNOCKOUT
Targeted mutation of mice embryonic
stem cells
Developmental = No data Muglia et al. (1995)
CRF OVEREXPRESSION
Transgenic CRF-OE mice under
metallothionein promoter
Developmental ↑ No data Stenzel-Poore et al. (1992)
Transgenic CRF-OE2122 mice C57BL/6J
background
Developmental No data No data Groenink et al. (2002)
Lentiviral based overexpression in mice Central amygdala (1); bed nucleus of
the stria terminalis (2)
(1) ↑
(2) =
(1) =
(2) ↑
Regev et al. (2011)
Lentiviral based overexpression in mice Central amygdala ↑ ↑ Keen-Rhinehart et al. (2009)
Ucn1 KNOCKOUT
Ucn1 gene replacement with
neomycin-resistant gene cascette on
C57BL/6 background (mice)
Developmental ↑ No data Vetter et al. (2002)
Mice embryonic stem cell technology Developmental = No data Wang et al. (2002)
Mice embryonic stem cell technology Developmental No data No data Zalutskaya et al. (2007)
Ucn2 KNOCKOUT
Replacement Ucn2 open reading frame
by a tau-lacZ reporter gene in mice
Developmental = ↓ Breu et al. (2012)
Ucn2 gene replacement with
neomycin-resistant gene cascette on
C57BL/6 background in mice
Developmental = ↓ Chen et al. (2006)
Ucn3 KNOCKOUT
Replacement Ucn3 open reading frame
by a tau-lacZ reporter gene in mice
Developmental = = Deussing et al. (2010)
Ucn1 AND 2 DOUBLE KNOCKOUT
Crossbreeding Ucn1 and Ucn2 single
knockout mice on mixed C57BL/6×129
background (mice)
Developmental ↓ No data Neufeld-Cohen et al. (2010a)
Ucn1, 2, AND 3TRIPLE KNOCKOUT
Crossbreeding Ucn1, Ucn2, and Ucn3
single knockout mice on mixed
C57BL/6×129 background (mice)
Developmental ↑ No data Neufeld-Cohen et al. (2010b)
CRFR1 KNOCKOUT
Deletion of CRFR1 locus in mice
embryonic stem cells
Developmental ↓ No data Timpl et al. (1998)
Replacement of CRFR1 gene exons by
PGK-neo cascette (mice)
Developmental ↓ No data Smith et al. (1998)
Lentiviral-based CRFR1 interference
(mice)
Basolateral amygdala ↓ No data Sztainberg et al. (2010)
Cre mediated deletion of CRFR1 (mice) Anterior forebrain and limbic system ↓ No data Muller et al. (2003)
Cre mediated deletion of CRFR1 in mice Site specific knockouts in forebrain
glutamatergic neurons (1); forebrain
GABAergic neurons (2); midbrain
dopaminergic neurons (3); brainstem
serotonergic neurons (4)
(1) ↓
(2) =
(3) ↑
(4) =
No data Refojo et al. (2011)
Lentiviral based system of RNA
interference in mice
Globus pallidus ↑ No data Sztainberg et al. (2011)
(Continued)
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Table 1 | Continued
Experimental procedure Specificity Anxiety Depression Reference
CRFR2 KNOCKOUT
Homologous recombination in mice
embryonic stem cells
Developmental = No data Coste et al. (2000)
Targeted deletion of CRFR2 locus in
mice embryonic stem cells
Developmental ↑ ↑ Bale et al. (2000)
CRFR2 exon replacement with
neomycin-resistant gene cascette in
mice
Developmental ↑ No data Kishimoto et al. (2000)
Lentiviral based system of RNA
interference in mice
Bed nucleus of the stria terminalis ↑ No data Lebow et al. (2012)
CRFR 1 AND 2 DOUBLE KNOCKOUT
CRFR2 knockout mice bred to CRFR1
knockout mice on mixed 129:C57BL/6
background
Developmental ↑ No data Bale et al. (2002b)
CRFR2 knockout mice bred to CRFR1
knockout mice
Developmental No data No data Preil et al. (2001)
↑, indicates an increase; ↓, indicates a decrease; =, indicates no difference in anxiety- or depressive-like behavior as comparing mutant and wildtype animals.
exposure to restraint stress, these mice exhibited elevated levels
of ACTH and corticosterone, while showing reduced anxiety-like
behavior.
CRFR2 knockout
In contrast to CRFR1 deficient mice, CRFR2 deficient mice do not
show a consistent change in anxiety-like behavior. One study has
shown that CRFR2 knockouts produced no significant effects on
anxiety responses in the elevated plus maze or in an open field test
(Coste et al., 2000). Another study has demonstrated no behav-
ioral changes in the light-dark test, but appealingly, the CRFR2
knockout mice have increased anxiety in the elevated plus maze
and open field test (Kishimoto et al., 2000). These anxiogenic-
like effects may be influenced by the reported increase in CRF
mRNA in the central amygdala of the CRFR2 knockout mice
(Bale et al., 2000). This brain region is associated in the activa-
tion of diverse responses induced by stress (Davis, 1992). However,
some data suggests a sex effect of emotional behavior mediated by
CRFR2. Female knockout mice seem to have behavior comparable
to wild type littermates, while the male knockouts exhibit more
anxiogenic-like behavior (Kishimoto et al., 2000).
CRFR 1 and 2 double knockout
CRFR 1 and 2 double knockout mice, in terms on anxiety-like
behavior, displayed a sexually dichotomous phenotype (Preil et al.,
2001; Bale et al., 2002b). Female double mutant mice showed
reduced levels of anxiety-like behavior, while male double knock-
outs did not, compared to their wild type littermates (Bale et al.,
2002b). The behavioral phenotype of the double knockout model
generated by Preil et al. (2001) has not been researched yet.
DEPRESSION
Strong evidence links the stress response, and the sensitivity
to stressful encounters, to the development of depression (e.g.,
Nestler et al., 2002; de Kloet et al., 2005; McEwen et al., 2012).
While the stress response is essential for successful adaptation,
chronic stress can accelerate disease processes, and lead to depres-
sion or other mood disorders (Nestler et al., 2002). As follows
we will highlight some of the available large body of evidence
linking CRF family of neuropeptides and their receptors to the
development of depression.
CRF
Elevated CRF levels and decreased receptor expression have been
found in post-mortem examination of suicide victims. In addition,
disproportionate activation of the HPA-axis has been reported
in more than one-half of patients diagnosed with depression,
and these symptoms can be corrected by treatment with anti-
depressants (Holsboer, 1999). CRF was also found to be elevated
in cerebrospinal fluid of depressed patients, which was reversed
in patients treated with antidepressants (De Bellis et al., 1993;
Heuser et al., 1998). Reduced CRF binding sites in the frontal cor-
tex of suicide victims have also been identified (Nemeroff et al.,
1984, 1988). This was interpreted as central CRF overabundance
leading to CRFR desensitization, a common phenomenon for
G-protein coupled receptors (Holsboer and Ising, 2010). Further-
more, hypercortisolemia and impairment of negative feedback by
cortisol on the HPA-axis have also been attributed to elevated
CRF levels (Reul and Holsboer, 2002; Keck, 2006). In support
for a role for CRF overexpression in the pathobiology of depres-
sion, a recent study performed by Keen-Rhinehart et al. (2009), in
which CRF was chronically overexpressed in the central nucleus
of the amygdala in female rats revealed an amplified CRF con-
centration in the PVN and a decreased glucocorticoid negative
feedback, both markers which have previously been associated
with the pathophysiology of depression (Nemeroff et al., 1984,
1988). Depressive-like behavior was further confirmed in the
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forced swim test (FST; measures escape behavior and behavioral
despair), as mutant rats overexpressing CRF showed increased
floating times and reduced escape behavior (Keen-Rhinehart et al.,
2009).
No behavioral tests were performed on the CRF null mice cre-
ated by Muglia et al. (1995) and Weninger et al. (1999) to assess
depressive-like behavior.
Urocortins
A study where urocortin peptides have been injected i.c.v. into
mice (Tanaka and Telegdy, 2008) revealed that while Ucn1 had
no effect on the animal’s behavior, both Ucn2 and 3 displayed
strong antidepressant-like activity by decreasing immobility time
and increased climbing and swimming behavior in a FST (Tanaka
and Telegdy, 2008). Moreover, single nucleotide polymorphisms
(SNP) located in the gene for Ucn3 have also been associated with
the antidepressant response (Wong et al., 2008). While a study
assessing levels of Ucn1 and 2 has not found any significantly
changes in patients suffering from major depressive disorder vs.
controls (Kang et al., 2007), Ucn1 mRNA is markedly upregu-
lated in the EWcp in depressed male suicide victims, compared
to healthy males (Kozicz et al., 2008). This upregulation was not
observed in female suicide victims, suggesting a gender specific
neuropathology (Kozicz et al., 2008).
In animal models for depression, Ucn2 knockout mice showed
a significant decrease in depressive-like behavior as assessed by the
FST. These effects were only evident in the female null mice, sug-
gesting a role for Ucn2 in mediating the sex differences observed in
the stress response (Wang et al., 2002; Chen et al., 2006) albeit in an
opposite direction as Ucn1 may (Kozicz et al., 2008). In contrast,
mice deficient for Ucn3 have unchanged depressive-like behavior
compared to wild type mice (Deussing et al., 2010).
CRFR1
CRFR1 activation of CRFR1 has been associated with anxiety or
depressive-like behaviors, which could be treated by administrat-
ing CRFR antagonists in patients suffering from major depression
(Kehne and Cain, 2010). Furthermore, quantitative PCR analyses
have shown that mRNA for CRFR1, but not CRFR2, is reduced
in the frontopolar cortex in suicide brains, which might be sec-
ondary to high CRF or Ucn1 levels (Merali et al., 2004; Kozicz
et al., 2008). These data suggests that at least for CRFR1, dysreg-
ulation in the forebrain may contribute to the neuropathology of
depression. To date, major pharmaceutical companies are focusing
on CRFR1 as the primary target for antidepressant development.
However, limited phase 2/3 clinical trial results with two CRFR1
antagonists, suggest a lack of efficacy in patients suffering from
major depressive disorder (Kehne and Cain, 2010). This suggests
that an overall inhibition of CRFR1 does not inhibit depressive-
like behavior, which could mean a more complex role for CRFR1
in mediating mood disorders (see later in text).
CRFR2
The role of CRFR2 is more complex, as the receptor has been asso-
ciated with enhancement as well as inhibition of stress responsivity
(Kehne and Cain, 2010). More specifically, CRFR2 deficient mice
tested in the FST displayed increased immobility which indicates
depressive-like behavior (Bale and Vale, 2003; Todorovic et al.,
2005) which could be effectively reversed by the CRFR1 antagonist
antalarmin (Bale and Vale, 2003).
Taken together, the findings listed above have led to the notion
that activation of CRFR1 is responsible for the initiation of the
stress response and mediates a rather pro anxiety/depression
behavior (Table 1). In contrast, CRFR2 is involved in the recov-
ery phase of the stress response, and exhibit a more anxiolytic
anti-depression function (Table 1). Although a great deal of exper-
imental evidence supported this dualistic action of CRFR1 and
CRFR2 in health and disease, not all data are in favor of this
notion. Consequently, the fundamental question has recently been
raised; are the endocrine, physiological and behavioral changes
controlled/mediated by CRFR1 and CRFR2 the consequence of
a balanced, dualistic function of these receptors or in a broader
sense that of CRF system components? Or can we possibly iden-
tify specific brain regions and/or neuron populations responsible
for the endocrine, physiological and behavioral stress response?
Recent technical developments have allowed us to directly address
this issue by creating unique animal models.
FINDINGS THAT CHALLENGE THE DUALISTIC ACTION OF
CRFR1 AND CRFR2 IN STRESS (MAL)ADAPTATION
Conditional mutagenesis of CRFR1 using a Cre-Lox system has
led to the development of various conditional knockouts were
CRFR1 has been deleted in specific neuron populations previously
implicated in stress and stress-associated anxiety and depres-
sion: (a) CRFR1GLU-CKO, where CRFR1 is deleted in forebrain
glutamatergic neurons; (b) CRFR1GABA-CKO, deleting the recep-
tor in forebrain GABAergic neurons; (c) CRFR1DA-CKO, carry-
ing CRFR1 deletion in midbrain dopaminergic neurons; and (d)
CRFR15HT-CKO, deleting CRFR1 in brainstem serotonergic neu-
rons (Refojo et al., 2011) (Figure 2). The roles of the different
neuronal populations expressing CRFR1 on emotional behavior,
these knockouts were subjected to a series of tests. CRFR1GLU-CKO
mice showed reduced anxiety-like behavior pointing toward a cen-
tral role of glutamate neurotransmission in stress induced anxiety.
These mice lack CRFR1 expression in glutamatergic neurons in the
hippocampus and amygdala, two important limbic regions in the
neuropathology of mood disorders (Refojo et al., 2005; Sanacora
et al., 2008). In line with these data, CRFR1Glu-CKO animals also
show impairments in CRF-induced changes on excitatory neuro-
transmission in these limbic regions (Refojo et al., 2011). It was
also shown that CRFR1 facilitates neuronal activity propagation
from the classical hippocampal input region (dentate gyrus) to
the CA1 output area. In conclusion, activation of CRFR1 in lim-
bic glutamatergic neurons, as it would in response to a stressor,
modulates glutamatergic neurotransmission, giving rise to neu-
ronal excitation in the hippocampal network, and consequently
anxiogenesis (Refojo et al., 2011).
Unexpectedly, for CRFR1DA-CKO, an increase in anxiety-
like behavior was found, whereas for CRFR1GABA-CKO and
CRFR15HT-CKO no anxiety-related behavioral changes were
observed (Refojo et al., 2011). As to the CRFR1DA-CKO, the dele-
tion of CRFR1 in dopaminergic neurons in the midbrain ventral
tegmental area and substantia nigra pars compacta (VTA/SNpc),
together with the fact that CRF increases the action potential
www.frontiersin.org March 2013 | Volume 4 | Article 28 | 7
Janssen and Kozicz CRF receptors in stress
FIGURE 1 | Schematic cross-section of the mouse brain showing site
specific overexpression of CRF and the resulting change on anxiety- or
depressive-like behavior. Areas of interest are the Bed nucleus of the
Stria Terminalis (BST) (Regev et al., 2011), central nucleus of the Amygdala
(CeA) (Keen-Rhinehart et al., 2009; Regev et al., 2011), and the
paraventricular nucleus (PVN) (Elliott et al., 2010). *Change in anxiety- or
depressive-like behavior is dependent on the conditions the mice were
subjected to. AON, anterior olfactory nucleus; Apit, anterior pituitary; ARC,
arcuate nucleus; BLA, basolateral amygdala; BST, bed nucleus of the stria
terminalis; CA1-3, fields CA1-3 of Ammon’s horn; CC, corpus callosum;
CeA, central nucleus of the amygdala; Cereb, cerebellum; CingCx,
cingulate cortex; DBB, diagonal band of Broca; DG, dentate gyrus; EWcp,
centrally projecting Edinger–Westphal nucleus; FrCx, frontal cortex; IC,
inferior colliculus; IPit, intermediate pituitary; LC, locus coeruleus; LS,
lateral septum; MS, medial septum; NTS, nucleus tractus solitarii; OB,
olfactory bulb; OccCx, occipital cortex; PAG, periaqueductal gray; ParCx,
parietal cortex; PPit, posterior pituitary; PVN, paraventricular nucleus; RN,
raphe nuclei; SC, superior colliculus; SN, substantia nigra; SON, supraoptic
nucleus; VLM, ventrolateral medulla; VMH, ventromedial hypothalamus;
VTA, ventral tegmental area.
firing of dopamine neurons in the VTA (Wanat et al., 2008) are
important to control the animal’s mood. It was also shown that
CRFR1DA-CKO displayed a decreased response to stress induced
dopamine release in the prefrontal cortex (PFC), indicating that
CRFR1 targets dopamine cells to control dopamine release into the
PFC under stressful conditions (Refojo et al., 2011). The findings
mentioned above strongly imply that stress-associated anxiety-
like behavior might be a consequence of an imbalance between
CRFR1 controlled glutamatergic and dopaminergic neuronal pop-
ulations involved in mediating emotional behavior (Refojo et al.,
2011).
In addition, the contrasting roles for CRFR1 expressed by
dopaminergic vs. glutamatergic neurons suggest that under phys-
iological conditions, CRF and CRFR1 controlled glutamatergic
and dopaminergic systems might function in an antagonistic
manner to maintain adaptive anxiety responses during periods
of stress (Refojo et al., 2011). The fact that simultaneous dele-
tion of CRFR1 in both glutamatergic and dopaminergic neurons
do not show alterations in anxiety-like behavior, supports this
notion.
A neuron population specific role for CRF system components
in mediating stress-associated emotional response is further sup-
ported by a study by Sztainberg et al. (2011). These authors have
demonstrated that a viral-mediated specific knock-down (KD)
of CRFR1 in the globus pallidus results in increased anxiety-
like behavior in mice (Sztainberg et al., 2011) (Figure 2). Earlier
studies have demonstrated that this region is a key mediator
of anxiety behavior, as it is associated with motor and asso-
ciative functions (Baumann et al., 1999; Critchley et al., 2001;
Kita, 2007; Sztainberg et al., 2011). In contrast CRFR1 expressed in
the basolateral amygdala mediates anxiogenic behaviors in mice,
further substantiating the view that the very same receptor can
mediate opposing behavioral responses depending on the brain
site of action (Sztainberg et al., 2010) (Figure 2).
To date there is only one study examining a site specific action of
CRFR2. A lentiviral KD of CRFR2 specifically in the bed nucleus of
the stria terminalis reduces susceptibility to stress induced anxiety
in an animal model for post-traumatic stress disorder, suggesting
an important role for CRFR2 in stress coping (Lebow et al., 2012)
(Figure 2).
With regard to CRF, a site specific action can also been pro-
posed. More specifically, prolonged and site specific overexpres-
sion of CRF in the central amygdala attenuates stress induced
anxiety-like behaviors without effecting depression-like behavior,
whereas CRF overexpression in the bed nucleus of the stria termi-
nalis increased depressive-like behavior, without affecting anxiety
levels in male mice (Regev et al., 2011) (Figure 1). Somewhat
conflicting data were reported in a mouse model, in which unre-
strained CRF synthesis in CeA produced a dysregulation of the
HPA-axis, depression-like behavior, as well as physiological and
reproductive consequences associated with stress-related disorders
(Keen-Rhinehart et al., 2009) (Figure 1).
Using two lentiviral-based approaches to specifically KD or
conditionally overexpress (OE) CRF in the CeA of adult mice
anxiety- and depression-like behaviors were evaluated under basal
and stressful conditions. Intriguingly, changing CeA-CRF levels
mildly affected anxiety-like behaviors under basal conditions. In
contrast, following exposure to an acute stressor, CeA-CRF-KD
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FIGURE 2 | Schematic cross-section of the mouse brain showing site
specific knockouts of either CRF receptor 1 or 2 and the associated
neurotransmitter specificity. Colored arrows show the direction of
change on anxiety-like behavior in mice which lack CRFR1 in specific brain
areas (Refojo et al., 2011). *In one study, CRFR1 was deleted in only the
GP (Sztainberg et al., 2011), while in another study CRFR1 was deleted in
all areas expressing GABA (Refojo et al., 2011). Other areas of interest are
the basolateral Amygdala (BLA) (Sztainberg et al., 2010) and Bed nucleus
of the Stria Terminalis (BST) (Lebow et al., 2012). AON, anterior olfactory
nucleus; Apit, anterior pituitary; ARC, arcuate nucleus; BLA, basolateral
amygdala; BST, bed nucleus of the stria terminalis; CA1-3, fields CA1-3 of
Ammon’s horn; CC, corpus callosum; CeA, central nucleus of the
amygdala; Cereb, cerebellum; CingCx, cingulate cortex; DBB, diagonal
band of Broca; DG, dentate gyrus; EWcp, centrally projecting
Edinger–Westphal nucleus; FrCx, frontal cortex; GP, globus pallidus; IC,
inferior colliculus; IPit, intermediate pituitary; LC, locus coeruleus; LS,
lateral septum; MS, medial septum; NTS, nucleus tractus solitarii; OB,
olfactory bulb; OccCx, occipital cortex; PAG, periaqueductal gray; ParCx,
parietal cortex; PPit, posterior pituitary; RN, raphe nuclei; RTN, reticular
thalamic nucleus; SC, superior colliculus; SN, substantia nigra; SON,
supraoptic nucleus; VLM, ventrolateral medulla; VMH, ventromedial
hypothalamus; VTA, ventral tegmental area.
strongly attenuated stress induced anxiety-like behaviors, whereas
a short-term CeA-CRF-OE enhanced the stress induced effects on
these behaviors (Regev et al., 2012). This study suggests that an
adequate behavioral response to stress is not only determined by
the level and site of expression of CRF system components, but
depends also on the condition an animal is exposed to.
Based on the pioneering studies discussed above (for overview
see Table 1 as well as Figures 1 and 2), a picture is emerging that
the roles of CRF system components in the animal’s stress response
and mood cannot be simplified to a dualistic model of action, but
are rather linked to the recruitment of specific brain areas and neu-
ron populations. Therefore, researches in the field must embark
on a long journey to systematically and comprehensively exploring
the significance of the many brain areas and neuron populations
expressing one or several of the CRF system components, before
we can conclude on the role(s) of CRFR1 and CRFR2 in health
and disease.
CONCLUSION
Taken together, recent studies using conditional mutagenesis or
viral knock-down or overexpression of CRF system components
strongly indicate that the involvement of CRF system components
in stress-associated anxiety and depression-like behavior cannot be
explained by a universal and brain wide mechanisms, and there-
fore the earlier proposed dualistic action of CRFR1 and CRFR2
in stress may not hold. Rather, CRF system components would
be specifically recruited in particular functional neuronal circuits,
which in turn would allow the expression of the necessary and suf-
ficient endocrine, physiological, and behavioral responses to stress
as conditions dictate.
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